General Statement of Disclosure:

CONSULTING FEES/HONORARIA: EBR(SIGNIFICANT), Biosense-Webster(SIGNIFICANT), Medtronic-Cryocath(SIGNIFICANT), Boston Scientific(SIGNIFICANT), Impulse Dynamics(SIGNIFICANT), Philips(MODEST), Abbott Inc(SIGNIFICANT), Cardionomiccs(SIGNIFICANT), CardioNXT(SIGNIFICANT), AFTx(SIGNIFICANT), Biotronik(SIGNIFICANT), AtriAN(SIGNIFICANT), Fire1(SIGNIFICANT), CoreMap(SIGNIFICANT), Novo Nordisk Inc.(MODEST), Cairdac(SIGNIFICANT) EQUITY INTERESTS/STOCK OPTIONS: Surecor(SIGNIFICANT), kardium(SIGNIFICANT), Newtrace(SIGNIFICANT), CoRISMA(SIGNIFICANT), Restore Medical(SIGNIFICANT), Dinova Hangzhou Nuomao Medtech, Ltd(SIGNIFICANT), Intershunt(SIGNIFICANT), HRT(SIGNIFICANT), CardiaCare(SIGNIFICANT), APN Health(SIGNIFICANT), Biostar Ventures(SIGNIFICANT), Soundcath(SIGNIFICANT), DRS Vascular(SIGNIFICANT), Vizaramed(SIGNIFICANT) OWNERSHIP/PARTNERSHIP/PRINCIPAL: Manual Surgical Sciences, Inc(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Epix Therapeutics(SIGNIFICANT), Acutus Medical(SIGNIFICANT), Affera Inc(SIGNIFICANT), Apama Medical(SIGNIFICANT), Autonomix Inc(SIGNIFICANT), Biosig Inc(SIGNIFICANT), Circa(SIGNIFICANT), Farapulse(SIGNIFICANT), Middlepeak(SIGNIFICANT), VytronUS(SIGNIFICANT), Keystone(SIGNIFICANT), Valcare(SIGNIFICANT), Medlumics(SIGNIFICANT), LuxCath(SIGNIFICANT), Corvia Medical(SIGNIFICANT), EP Dynamics(SIGNIFICANT), Epi EP(SIGNIFICANT), Javelin(SIGNIFICANT), Axon(SIGNIFICANT), Backbeat(SIGNIFICANT), East End Medical(SIGNIFICANT), Eximo(SIGNIFICANT), Newpace(SIGNIFICANT), Laminar(SIGNIFICANT), Field Medical(SIGNIFICANT), Focused Therapeutics(SIGNIFICANT), Anumana(SIGNIFICANT), Atacor(SIGNIFICANT), Aquaheart(SIGNIFICANT), Cardiofocus(SIGNIFICANT), Nyra Medical(SIGNIFICANT)

View Full Disclosure